Tamoxifen quotes

"(Tamoxifen) is a garbage drug that made it to the top of the scrap heap.  It is DES in the making."--Pierre Blais (Tamoxifen: A Major Medical Mistake? by Sherrill Sellman). http://www.ssellman.com/hh_tamoxifen.html

Uterine cancer is one of the possible side-effects of Tamoxifen. One study showed that 27 per cent of women taking Tamoxifen showed hyperplastic (unfavourable new growth) changes in their wombs within 15 months. Tamoxifen is carcinogenic and can cause an early menopause, osteoporosis, endometrial cancer, liver cancer and clotting disease. Taking 20 milligrams of Tamoxifen per day can increase the risk for developing endometrial cancer by up to five times. Clotting disorders are seven times more frequent. One study showed just a meagre 0.7 per cent benefit for women taking Tamoxifen preventively to reduce the risk of developing further tumours in the breast. HORMONE HERESY - Oestrogen's Deadly Truth -by Sherrill Sellman

I worked for Array Biopharma designing Tamoxifen derivatives for Eli Lilly. Because Tamoxifen was shown to ignite higher cancer rates among women, Eli Lilly hoped to replace it by developing a new "chemical cousin." We were unsuccessful in our attempts. Despite its known danger, Tamoxifen remained on the market. I noticed that ads from Eli Lilly for Tamoxifen insisted that it might decrease cancer risk. This was the exact opposite of what biochemists found in the lab and reported. [2006] Interview of Shane Ellison author of Health Myths Exposed

A 42-year-old woman with metastatic breast cancer developed bilateral optic disc swelling, retinal hemorrhages, and visual impairment three weeks after starting treatment with low doses of tamoxifen. Neurologic evaluation failed to provide an explanation for the ocular findings which resolved completely after cessation of tamoxifen therapy. This case suggests that tamoxifen has the potential for causing serious ophthalmologic toxicity which may be reversible if recognized early.  Tamoxifen citations

A 57-year-old woman developed bilateral optic neuritis after being treated for 6 months with tamoxifen in the dosage of 30 to 40 mg orally a day. As the neuritis progressed during continued treatment and no other causal explanation could be found, tamoxifen was stopped and the optic neuritis regressed. Since tamoxifen might cause optic neuritis the authors recommend the monitoring of ocular symptoms in treated patients Tamoxifen citations

 Specific ocular complications, namely retinopathy, keratopathy and optic neuritis, have been described in women being treated with tamoxifen for metastatic breast cancer or taking this drug as an adjuvant postoperative therapy. We examined 61 patients who had been using tamoxifen for at least one year, in order to detect the incidence of ocular complications. Two patients had retinopathy after having taken high cumulative doses of tamoxifen. Another had corneal deposits and a fourth had optic neuritis. It thus appears that systematic screening of all symptom-free patients using this drug for metastatic breast cancer is superfluous. However, an ophthalmological assessment every two years or earlier in case of visual complaints for patients taking tamoxifen as an adjuvant therapy remains useful, because the oncological therapy can be adjusted if serious ocular complications arise. Tamoxifen citations

Studies show that women taking tamoxifen after surviving breast cancer then have a high propensity to develop endometrial cancer. The NCI and Zeneca Pharmaceuticals, which makes the drug, aggressively lobbied State of California regulators to keep them from adding tamoxifen to their list of carcinogens.  Zeneca is one of the sponsors of Breast Cancer Awareness Month.

That the NCI and ACS have embarked on unethical trials with two hormonal drugs, tamoxifen and Evista, in ill-conceived attempts to prevent breast cancer in healthy women while suppressing evidence that these drugs are known to cause liver and ovarian cancer, respectively, and in spite of the short-term lethal complications of tamoxifen. The establishment also proposes further chemoprevention trials this fall on tamoxifen, and also Evista, in spite of two published long-term European studies on the ineffectiveness of tamoxifen. This represents medical malpractice verging on the criminal. -----Epstein http://www.preventcancer.com/